MedWatch

New type of flu-vaccine FDA-approved

A new type of flu-vaccine from Novartis has been approved by the FDA. The US health authorities have also contributed to the expensive, new technology, which makes it possible to stock up faster than previously.

Foto: Colourbox

In 2006 Novartis won a 220-million-dollar contract from the US health authorities concerning the development of a new type of flu, and in 2009 the same authorities invested 487 million dollars in the company’s US production facilities.

And now the FDA has approved Novartis’ flu-vaccine, Flucelvax, the first of its kind, produced with a completely new technology. It happens after an FDA advisory panel did not recommend the vaccine for approval in November 2009, saying more safety data was needed.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier